Introduction: Sickle cell disease is a real public health problem in the world and particularly in Niger where the prevalence of the S gene is estimated at 25% and that of the homozygous forms at between 1% and 2%. Treatment combines quarterly follow-up of patients and management of complications. The objective of this study was to identify the potential explanatory factors of non-adherence to treatment in sickle cell patients followed at the national reference center for sickle cell disease in Niger. Methods: This is a cross-sectional study of sickle cell cases followed at the CNRD in Niger. The population consisted of all sickle cell patients followed in this center in 2021. The data collection techniques were individual interviews and documentary reviews. Non-adherence was assessed with the Girerd test. Descriptive statistical tests and simple and multiple logistic regression models were performed. Results: A total of 368 patients were enrolled. The median age is 7 years (4; 10) and the sex ratio is 1.04. Ninety-eight (98) or 26.6% were compliant and 270 (73.4%) were non-compliant. In multivariate analysis, the factors independently and negatively associated with non-adherence to treatment were schooling (adjusted OR [95% CI], p-value), 0.17 [0.10 - 0.30]; p < 0.0001); discontinuation of treatment [OR = 0.15 [0.05 - 0.43], p < 0.0004; the distance from the Center 0.58 [0.33 - 0.99)], p ≤ 0.0489. Unawareness of the disease was positively and significantly associated with non-adherence 7.68 [2.20 - 26.72], p ≤ 0.0014. Conclusion: The factors influencing treatment compliance identified in this study are all modifiable. To prevent the complications of sickle cell disease, we must fight against ignorance, make care services accessible and make care free.
References
[1]
Pinto, V.M., Balocco, M., Quintino, S. and Forni, G.L. (2019) Sickle Cell Disease: A Review for the Internist. Internal and Emergency Medicine, 14, 1051-1064. https://doi.org/10.1007/s11739-019-02160-x
[2]
Scheen, A.J. and Giet, D. (2010) Non-observance thérapeutique: causes, conséquences, solutions. Revue Médicale de Liège, 65, 239-245.
[3]
Cottina, Y., Lorgisa, L., et al. (2012) Medication Compliance: concepts and Determinants. Elsevier Masson SAS. https://doi.org/10.1016/S1878-6480(12)70845-5
[4]
Teach, S.J., Lillis, K.A. and Grossi, M. (1998) Compliance with Penicillin Prophylaxis in Patients with Sickle Cell Disease. Archives of Pediatrics and Adolescent Medicine, 152, 274-278. https://doi.org/10.1001/archpedi.152.3.274
[5]
Curtis, K., Lebedev, A., Aguirre, E. and Lobitz, S.A. (2019) Medication Adherence App for Children with Sickle Cell Disease: Qualitative Study. JMIR MHealth UHealth, 7, e8130. https://doi.org/10.2196/mhealth.8130
[6]
Loiselle, K., Lee, J.L., et al. (2016) Systematic and Meta-Analytic Review: Medication Adherence among Pediatric Patients with Sickle Cell Disease. Journal of Pediatric Psychology, 41, 406-418. https://doi.org/10.1093/jpepsy/jsv084
[7]
Candrilli, S.D., O’Brien, S.H., et al. (2011) Hydroxyurea Adherence and Associated Outcomes among Medicaid Enrollees with Sickle Cell Disease. American Journal of Hematology, 86, 273-277. https://doi.org/10.1002/ajh.21968
[8]
Doglioni, D.O. (2021) Psychosocial Factors Influencing Treatment Compliance in Adults with Sickle Cell Disease. 465.
[9]
Adewoyin, A.S., Oghuvwu, O.S. and Awodu, O.A. (2017) Hydroxyurea Therapy in Adult Nigerian Sickle Cell Disease: A Monocentric Survey on Pattern of Use, Clinical Effects and Patient’s Compliance. African Health Sciences, 17, 255-261. https://doi.org/10.4314/ahs.v17i1.31
[10]
Lainé, A. (2007) Parents of Sickle Cell Children Facing the Disease and the Healthcare System.